Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 1350

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 15
Chunk 1350
---
ufosfamide, an investigational treatment for pancreatic cancer. The platform
will evaluate the current trajectory of the trial with respect to safety signals, extract predictive biomarkers for efficacy and safety
performance from prior studies to support future trial design, and provide data-driven insights to optimize Eleison’s planned clinical
trials for inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). These insights are expected to streamline trial efficiency
and improve decision-making for Eleison’s broader oncology pipeline.

In
March 2025, the Company anticipates making a severance payment to a former employee for approximately $45,000.

 F-18